We also explored the possible links between ZNF419 expression and the tumor immune microenvironment and mutation status based on five typical cancers, including lung squamous cell carcinoma (LUSC), bladder urothelial carcinoma (BLCA), kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and prostate adenocarcinoma (PRAD). The gene discussed is ZNF419; the disease is prostate adenocarcinoma.